Email this article USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE
- Authors: Fedorova N.V.1, Gubanova Y.N.1
-
Affiliations:
- Center of Extrapyramidal Diseases, Department of Neurology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow
- Issue: Vol 8, No 1 (2014)
- Pages: 77-81
- Section: CASE REPORT
- Published: 23.11.2014
- URL: https://klinitsist.abvpress.ru/Klin/article/view/152
- DOI: https://doi.org/10.17650/1818-8338-2014-1-77-81
- ID: 152
Cite item
Full Text
Abstract
The paper considers a clinical case of early-stage mixed Parkinson’s disease (PD) with significant affective disorders and restless legs syndrome. Once-daily extended-release pramipexole 3 mg significantly improved a patient’s status and led to regression of movement and affective disorders. The paper gives data on the efficacy of dopamine receptor agonists in treating PD and the benefits of their extended-release formulations.
About the authors
N. V. Fedorova
Center of Extrapyramidal Diseases, Department of Neurology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow
Author for correspondence.
Email: natalia.fedorova@list.ru
Russian Federation
Ye. N. Gubanova
Center of Extrapyramidal Diseases, Department of Neurology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowRussian Federation
References
Supplementary files
